Respiratory disturbance during L-dopa treatment of Parkinson's syndrome.
D000284:Administration, Oral; D001049:Apnea / Q000139:chemically induced*; D002250:Carbon Radioisotopes; D002746:Chlorpromazine / Q000008:administration & dosage / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use / Q000652:urine; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy* / Q000378:metabolism; D010919:Placebos; D013997:Time Factors
D002250:Carbon Radioisotopes; D010919:Placebos; D004295:Dihydroxyphenylalanine; D010100:Oxygen; D002746:Chlorpromazine